Comparison of long-term treatment outcomes of laser and anti-VEGF therapy in retinopathy of prematurity: a multicentre study from J-CREST group.

Autor:	Murakami T; Japan-Clinical Retina Study Group (J-CREST), Kagoshima, Japan. tomoyam618@gmail.com.; Department of Ophthalmology, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan. tomoyam618@gmail.com., Okamoto F; Japan-Clinical Retina Study Group (J-CREST), Kagoshima, Japan.; Department of Ophthalmology, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan., Kinoshita T; Japan-Clinical Retina Study Group (J-CREST), Kagoshima, Japan.; Department of Ophthalmology, Sapporo City General Hospital, Sapporo, Japan., Shinomiya K; Japan-Clinical Retina Study Group (J-CREST), Kagoshima, Japan.; Department of Ophthalmology, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan., Nishi T; Japan-Clinical Retina Study Group (J-CREST), Kagoshima, Japan.; Department of Ophthalmology, Nara Medical University, Nara, Japan., Obata S; Japan-Clinical Retina Study Group (J-CREST), Kagoshima, Japan.; Department of Ophthalmology, Shiga University of Medical Science, Otsu, Japan., Ogura S; Japan-Clinical Retina Study Group (J-CREST), Kagoshima, Japan.; Department of Ophthalmology and Visual Science, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan., Nishihara Y; Japan-Clinical Retina Study Group (J-CREST), Kagoshima, Japan.; Department of Ophthalmology, Graduate School of Medicine, Kurume University, Kurume, Japan., Tsukitome H; Japan-Clinical Retina Study Group (J-CREST), Kagoshima, Japan.; Department of Ophthalmology, Graduate School of Medicine, Mie University, Tsu, Japan., Jujo T; Japan-Clinical Retina Study Group (J-CREST), Kagoshima, Japan.; Department of Ophthalmology, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan., Ueda K; Japan-Clinical Retina Study Group (J-CREST), Kagoshima, Japan.; Division of Ophthalmology, Department of Surgery, Graduate School of Medicine, Kobe University, Kobe, Japan., Ishii R; Department of Biostatistics, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan., Oshika T; Japan-Clinical Retina Study Group (J-CREST), Kagoshima, Japan.; Department of Ophthalmology, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan.
Jazyk:	angličtina
Zdroj:	Eye (London, England) [Eye (Lond)] 2023 Dec; Vol. 37 (17), pp. 3589-3595. Date of Electronic Publication: 2023 May 06.
DOI:	10.1038/s41433-023-02559-z
Abstrakt:	Objectives: To compare real-world, long-term outcomes of laser and anti-vascular endothelial growth factor (VEGF) therapies in patients with retinopathy of prematurity (ROP). Methods: This was a multicentre retrospective study. We included 264 eyes of 139 patients treated for type 1 ROP or aggressive ROP (AROP) who were followed for at least 4 years. Laser treatment was initially performed in 187 eyes (the laser group), and anti-VEGF therapy was initially performed in 77 eyes (the anti-VEGF group). We collected data on sex, birth characteristics, zone, stage, and the presence of plus disease at the time of treatment and best-corrected visual acuity (BCVA), spherical equivalent (SE), and ocular complications (amblyopia and strabismus) in patients aged 4-6 years. We investigated the associations between treatment outcomes (BCVA, SE and the presence of amblyopia and strabismus) and influencing factors, including treatment procedure (anti-VEGF or laser therapy), sex, birth characteristics, zone, stage, and the presence of plus disease, using multivariable analysis and logistic regression analyses. Results: The initial treatment procedure was not associated with any specific treatment outcome. Subgroup analysis of patients with zone I ROP revealed that the anti-VEGF-treated eyes had significantly better BCVA and higher SE than laser-treated eyes (p = 0.004, p = 0.009, respectively). Female patients presented significantly better BCVA, less amblyopia and less strabismus than male patients (p < 0.001, p = 0.029, p = 0.008, respectively). Conclusions: In zone I ROP, anti-VEGF therapy led to better visual acuity and less myopic refractive error than laser treatment. (© 2023. The Author(s), under exclusive licence to The Royal College of Ophthalmologists.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu Full text from SpringerLink